21PBaseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab.
Saved in:
| Title: | 21PBaseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. |
|---|---|
| Authors: | Awada, G1 (AUTHOR), Özdemir, I2 (AUTHOR), Schwarze, J K1 (AUTHOR), Daeninck, E1 (AUTHOR), Gondry, O2 (AUTHOR), Jansen, Y3 (AUTHOR), Seremet, T1 (AUTHOR), Keyaerts, M2 (AUTHOR), Everaert, H2 (AUTHOR), Neyns, B1 (AUTHOR) |
| Source: | Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdy493.019 |
